CARsgen Therapeutics grants significant equity incentives to employees and directors

CARsgen Therapeutics Holdings Limited has announced the grant of 6,740,500 options under its Post-IPO Share Option Scheme and 1,911,500 restricted share units (RSUs) under its Post-IPO RSU Scheme on September 18, 2025. The options, representing approximately 1.17% of total issued shares, were granted to 348 option grantees with an exercise price of HK$20.99 per share, vesting in annual 25% increments from September 18, 2026, to September 18, 2029. The RSUs, approximately 0.33% of total issued shares, were granted to 196 RSU grantees with a similar vesting schedule.

The grants include significant allocations to executive directors and substantial shareholders. Dr. Zonghai Li, Dr. Huamao Wang, and Mr. Haiou Chen each received 100,000 options, while Dr. Hua Jiang received 42,000 options and 21,000 RSUs. The remaining 6,398,500 options were distributed among 344 other employees, and 1,890,500 RSUs to 195 other employees. These grants were approved by independent non-executive directors and are part of their remuneration, recognizing past contributions and aligning long-term interests with the company’s growth.

These equity grants are intended to reward employees for their past contributions, provide incentives for future contributions, and align their interests with CARsgen Therapeutics and its shareholders. Following these grants, 27,170,378 shares remain available for future option grants, and 16,625,154 shares are available for future RSU grants, both within the respective scheme mandate limits.